SERA

+ Watchlist + Portfolio

Sera Prognostics, Inc.

Regulated industry Sells to businessesTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.04
52-Week Range: $1.56 – $3.95
Market Cap: $82.45M
P/E (TTM): —
EPS (TTM): -0.67
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.39
PEG Ratio: —
Return on Equity: -45.03%
Return on Assets: -23.48%
Gross Margin: -150.00%
Operating Margin: -33346.67%
Profit Margin: 0.00%
Current Ratio: 1.98
Debt/Equity: 0.05
Total Debt: $3.00M
Free Cash Flow: $-18.89M
Revenue Growth: 76.50%
Earnings Growth: —
Enterprise Value: $39.01M

SERA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$268.00K	$306.00K	$77.00K	$81.00K
Cost of Revenue	$193.00K	$210.00K	$82.00K	$164.00K
Gross Profit	$75.00K	$96.00K	-$5.00K	-$83.00K
Research & Development	$14.24M	$15.22M	$14.73M	$13.17M
Selling, General & Admin	$31.48M	$24.69M	$21.90M	$23.25M
Operating Expenses	$45.73M	$39.92M	$36.63M	$36.42M
Operating Income	-$45.65M	-$39.82M	-$36.63M	-$36.50M
EBITDA	-$43.37M	-$35.29M	-$32.04M	-$30.98M
Pretax Income	-$44.19M	-$36.24M	-$32.90M	-$31.93M
Net Income	-$44.19M	-$36.24M	-$32.90M	-$31.93M
Diluted EPS	-1.43	-1.16	-0.99	-0.67
Diluted Shares	30.94M	31.20M	33.16M	47.66M

SERA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$29.88M	$3.88M	$4.04M	$3.94M
Receivables	$6.11M	$11.47M	$34.00K	$12.00K
Current Assets	$90.13M	$61.34M	$47.60M	$40.77M
Total Assets	$116.33M	$95.44M	$72.58M	$101.93M
Current Liabilities	$15.54M	$24.44M	$24.77M	$24.19M
Total Debt	$2.83M	$1.86M	$840.00K	$2.34M
Total Liabilities	$17.39M	$25.28M	$24.77M	$26.52M
Retained Earnings	-$210.65M	-$246.90M	-$279.79M	-$311.72M
Shareholders' Equity	$98.94M	$70.16M	$47.80M	$75.41M
Working Capital	$74.59M	$36.90M	$22.83M	$16.58M

SERA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$34.61M	-$27.19M	-$14.19M	-$25.62M
Capital Expenditure	-$791.00K	-$128.00K	-$1.10M	-$726.00K
Free Cash Flow	-$35.40M	-$27.32M	-$15.29M	-$26.35M
Depreciation & Amortisation	$756.00K	$900.00K	$833.00K	$940.00K
Stock-Based Compensation	$5.05M	$5.27M	$7.01M	$5.11M
Investing Cash Flow	$5.55M	$438.00K	$11.74M	-$28.50M
Financing Cash Flow	$5.00K	$752.00K	$2.61M	$54.03M
Net Change in Cash	-$29.05M	-$26.00M	$163.00K	-$99.00K

SERA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$38.00K	$17.00K	$16.00K	$10.00K	$14.00K	$30.00K
Cost of Revenue	$40.00K	$41.00K	$41.00K	$42.00K	$42.00K	$50.00K
Gross Profit	-$2.00K	-$24.00K	-$25.00K	-$32.00K	-$28.00K	-$20.00K
Research & Development	$3.33M	$3.34M	$3.28M	$3.22M	$3.03M	$3.49M
Selling, General & Admin	$5.91M	$5.96M	$5.67M	$5.71M	$6.30M	$6.49M
Operating Expenses	$9.25M	$9.30M	$8.96M	$8.92M	$9.33M	$9.98M
Operating Income	-$9.25M	-$9.32M	-$8.98M	-$8.95M	-$9.36M	-$10.00M
EBITDA	-$7.97M	-$7.81M	-$7.57M	-$7.64M	-$8.20M	-$8.95M
Pretax Income	-$8.19M	-$8.05M	-$7.81M	-$7.88M	-$8.40M	-$9.14M
Net Income	-$8.19M	-$8.05M	-$7.81M	-$7.88M	-$8.40M	-$9.14M
Diluted EPS	-0.20	-0.16	-0.16	-0.16	-0.17	-0.18
Diluted Shares	41.97M	49.07M	49.53M	49.98M	50.26M	50.48M

SERA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$5.23M	$5.02M	$4.08M	$3.94M	$4.17M	$4.40M
Receivables	$25.00K	$17.00K	$14.00K	$12.00K	$11.00K	$10.00K
Current Assets	$47.28M	$40.87M	$44.49M	$40.77M	$49.73M	$48.13M
Total Assets	$118.18M	$111.83M	$108.13M	$101.93M	$93.54M	$86.74M
Current Liabilities	$23.40M	$23.60M	$23.50M	$24.19M	$23.42M	$24.36M
Total Debt	$568.00K	$351.00K	$2.45M	$2.34M	$2.50M	$3.00M
Total Liabilities	$23.40M	$23.60M	$25.94M	$26.52M	$25.92M	$27.36M
Retained Earnings	-$287.98M	-$296.03M	-$303.84M	-$311.72M	-$320.12M	-$329.26M
Shareholders' Equity	$94.78M	$88.23M	$82.18M	$75.41M	$67.62M	$59.38M
Working Capital	$23.88M	$17.27M	$20.99M	$16.58M	$26.31M	$23.78M

SERA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$7.55M	-$5.47M	-$6.48M	-$6.12M	-$8.77M	-$6.31M
Capital Expenditure	-$3.00K	-$281.00K	-$112.00K	-$330.00K	-$8.00K	-$52.00K
Free Cash Flow	-$7.56M	-$5.75M	-$6.59M	-$6.45M	-$8.78M	-$6.36M
Depreciation & Amortisation	$216.00K	$237.00K	$243.00K	$244.00K	$193.00K	$191.00K
Stock-Based Compensation	$1.49M	$1.34M	$1.25M	$1.02M	$835.00K	$823.00K
Investing Cash Flow	-$44.80M	$5.24M	$5.17M	$5.89M	$8.98M	$6.39M
Financing Cash Flow	$53.54M	$18.00K	$373.00K	$93.00K	$20.00K	$140.00K
Net Change in Cash	$1.19M	-$214.00K	-$935.00K	-$137.00K	$231.00K	$223.00K

Market Snapshot

About

Sera Prognostics, Inc. is a women's health diagnostic company dedicated to improving maternal and neonatal health. The company develops and commercializes innovative proteomics-based tests to predict pregnancy complications, including preterm birth risk assessment. Sera Prognostics aims to provide healthcare providers with actionable insights to guide prenatal care decisions.